Tag: EBMT
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program – 04/15/2024 at 07:40
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program:• Positive…
MaaT Pharma to present promising clinical data for MaaT013, its most advanced drug candidate, at the 48th annual meeting of the EBMT – 03/17/2022 at 18:15
MaaT Pharma announces today that promising results from its Phase 2 clinical trial HERACLES (n=24) and its compassionate access program (n=52) for its most advanced microbiota drug candidate, MaaT013, will…